Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction

Trial Profile

Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2014

At a glance

  • Drugs Capecitabine (Primary) ; Carboplatin (Primary) ; Epirubicin (Primary) ; Fluorouracil (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms MEMORI
  • Most Recent Events

    • 01 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 13 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top